Dana White
UFC president answers a question at a press conference. Kenai Andrews/MMA Crossfire

MMA Crossfire – UFC’s Dana White backs NSAC’s decision to end TRT exemptions

The UFC backs the Nevada State Athletic Commission’s (NSAC) decision today to immediately end the use of testerone replacement therapy (TRT) for fighters in it’s jurisdiction.

In a statement released today, UFC President Dana White supported the NSAC edict.

“The Ultimate Fighting Championship fully supports the decision made today by the Nevada State Athletic Commission regarding the immediate termination of therapeutic use exemptions (TUE) for testosterone replacement therapy (TRT). We believe our athletes should compete based on their natural abilities and on an even playing field. We also intend to honor this ruling in international markets where, due to a lack of governing bodies, the UFC oversees regulatory efforts for our live events. We encourage all athletic commissions to adopt this ruling.”

Previously, White supported TRT use for UFC fighters.

TRT remains a thorny issue as some believe it is a performance enhancer and thus unfair to use.

Welcome back to The Crossfire.

MMA Crossfire

 

Fighters who use or have used TRT in the past include Dan Henderson, Chael Sonnen Forrest Griffin, and Vitor Belfort.

UFC on FX 7

In MMA, a Therapeutic Use Exemption (TUE) allows approved fighters with low testosterone blood levels to boost their levels, usually within a state athletic commission sanctioned limit.

Former NASC head Keith Kizer recently spoke about TRT in an interview with “The Fight Doctor” Jon Felber M.D. in detail.

UFC light-heavyweight champion Jon Jones is a staunch opponent of TRT use.

[email protected]

[email protected] MMA Crossfire – UFC’s Dana White backs NSAC’s decision to end TRT exemptions

Categories
Doping

Kenai is a former Postmedia Network online news and sports editor. He is the Editor-in-Chief for MMA Crossfire.

RELATED BY

Sign up for our free Crossfire Nation newsletter and get content directly to your email!
Share via
Copy link